TY - JOUR
T1 - Immunotherapy versus standard of care in metastatic renal cell carcinoma. A systematic review and meta-analysis
AU - Iacovelli, Roberto
AU - Ciccarese, Chiara
AU - Bria, Emilio
AU - Bimbatti, Davide
AU - Fantinel, Emanuela
AU - Mosillo, Claudia
AU - Bisogno, Iolanda
AU - Brunelli, Matteo
AU - Tortora, Giampaolo
AU - Porta, Camillo
N1 - Copyright © 2018 Elsevier Ltd. All rights reserved.
PY - 2018/11
Y1 - 2018/11
N2 - BACKGROUND: Recently, immune checkpoint inhibitors against PD-1/PD-L1 or CTLA4 have emerged as new treatments for metastatic renal cell carcinoma (mRCC), despite discrepancy between their effects on OS and PFS. We performed a meta-analysis of randomized trials comparing immunotherapy to standard of care (SOC) in mRCC.METHODS: Searching the MEDLINE/PubMed, Cochrane Library and ASCO Meeting abstracts prospective studies were identified. Data extraction was conducted according to the PRISMA statement. The measured outcomes were OS, PFS, and ORR.RESULTS: A total of 2832 patients were available for evaluation of OS, and 3033 for PFS and ORR. Compared to SOC, immunotherapy improved OS (HR = 0.75; 95%CI 0.66-0.85; p < 0.001), and PFS (HR = 0.88; 95%CI 0.80-0.97; p = 0.009). The PFS benefit was not confirmed when considering patients treated in first-line only (p = 0.10). Conversely, significant ORR improvement was found in patients treated in first-line only (HR = 1.14; 95%CI 1.02-1.28; p = 0.03) but not in the overall population.CONCLUSIONS: Immunotherapy improved OS compared to SOC in mRCC, irrespective of treatment line. In first-line, immunotherapy also increased the ORR compared to sunitinib. A lack of correlation between OS and PFS was confirmed, the latter to be used cautiously for the design and interpretation of trials involving immunotherapy in mRCC.
AB - BACKGROUND: Recently, immune checkpoint inhibitors against PD-1/PD-L1 or CTLA4 have emerged as new treatments for metastatic renal cell carcinoma (mRCC), despite discrepancy between their effects on OS and PFS. We performed a meta-analysis of randomized trials comparing immunotherapy to standard of care (SOC) in mRCC.METHODS: Searching the MEDLINE/PubMed, Cochrane Library and ASCO Meeting abstracts prospective studies were identified. Data extraction was conducted according to the PRISMA statement. The measured outcomes were OS, PFS, and ORR.RESULTS: A total of 2832 patients were available for evaluation of OS, and 3033 for PFS and ORR. Compared to SOC, immunotherapy improved OS (HR = 0.75; 95%CI 0.66-0.85; p < 0.001), and PFS (HR = 0.88; 95%CI 0.80-0.97; p = 0.009). The PFS benefit was not confirmed when considering patients treated in first-line only (p = 0.10). Conversely, significant ORR improvement was found in patients treated in first-line only (HR = 1.14; 95%CI 1.02-1.28; p = 0.03) but not in the overall population.CONCLUSIONS: Immunotherapy improved OS compared to SOC in mRCC, irrespective of treatment line. In first-line, immunotherapy also increased the ORR compared to sunitinib. A lack of correlation between OS and PFS was confirmed, the latter to be used cautiously for the design and interpretation of trials involving immunotherapy in mRCC.
KW - Antineoplastic Agents/therapeutic use
KW - Carcinoma, Renal Cell/drug therapy
KW - Humans
KW - Immunotherapy
KW - Kidney Neoplasms/drug therapy
KW - Prognosis
KW - Standard of Care
U2 - 10.1016/j.ctrv.2018.08.007
DO - 10.1016/j.ctrv.2018.08.007
M3 - Review article
C2 - 30145397
SN - 0305-7372
VL - 70
SP - 112
EP - 117
JO - Cancer Treatment Reviews
JF - Cancer Treatment Reviews
ER -